{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:22:00Z","timestamp":1787559720913,"version":"build-2736575974"},"reference-count":39,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"DOI":"10.1080\/14737167.2026.2715978","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:05:36Z","timestamp":1787558736000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["From \u201ccluster imitation\u201d to \u201cfirst generic\u201d: the impact of market exclusivity incentives on Chinese generic drug manufacturers"],"prefix":"10.1080","author":[{"given":"Zhixue","family":"Liu","sequence":"first","affiliation":[{"name":"Trinomab Biotechnology Co., Ltd","place":["Zhuhai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing Fumeiruixin Technology Co., Ltd","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing Fumeiruixin Technology Co. Ltd","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfa","family":"Chen","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_3_5_2_1","first-page":"644903","article-title":"Deconstructing and historicizing access to medicines: the changing priority of pharmaceutical governance in China","volume":"6","author":"Li L.","year":"2021","unstructured":"Li L. Deconstructing and historicizing access to medicines: the changing priority of pharmaceutical governance in China. Front Sociol. 2021;6:644903.","journal-title":"Front Sociol"},{"issue":"3","key":"e_1_3_5_3_1","first-page":"2376","article-title":"Towards sustainable drug supply in China: a bibliometric analysis of drug reform policies","volume":"15","author":"Yan S","year":"2023","unstructured":"Yan S, Pan L, Lu Y, et al. Towards sustainable drug supply in China: a bibliometric analysis of drug reform policies. Sustainability. 2023;15(3):2376.","journal-title":"Sustainability"},{"key":"e_1_3_5_4_1","first-page":"1129486","article-title":"Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry?","volume":"11","author":"Liu Q","year":"2023","unstructured":"Liu Q, Huang Z, Mao Z. Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? Front Public Health. 2023;11:1129486.","journal-title":"Front Public Health"},{"key":"e_1_3_5_5_1","doi-asserted-by":"crossref","first-page":"1512148","DOI":"10.3389\/fpubh.2025.1512148","article-title":"Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China","volume":"13","author":"Jiang M","year":"2025","unstructured":"Jiang M, Huang J, Wang S, et al. Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China. Front Public Health. 2025;13:1512148.","journal-title":"Front Public Health"},{"issue":"2","key":"e_1_3_5_6_1","article-title":"The impact of generic drug consistency evaluation policy on pharmaceutical enterprises: a supply-side perspective","volume":"17","author":"Siwen L","year":"2022","unstructured":"Siwen L, Yue Y. The impact of generic drug consistency evaluation policy on pharmaceutical enterprises: a supply-side perspective. Asian J Soc Pharm. 2022;17(2).","journal-title":"Asian J Soc Pharm"},{"key":"e_1_3_5_7_1","first-page":"11","article-title":"An empirical study of the impact of generic drug competition on drug market prices in China","author":"Yin C","year":"2023","unstructured":"Yin C, Pengcheng L, Haomiao N. An empirical study of the impact of generic drug competition on drug market prices in China. Front Public Health. 2023;11.","journal-title":"Front Public Health"},{"key":"e_1_3_5_8_1","first-page":"23","article-title":"The \u201cprice war\u201d in pharmaceutical industry: evidence from China\u2019s centralized procurement","volume":"11","author":"Yi Y","year":"2021","unstructured":"Yi Y, Teng L, Li X. The \u201cprice war\u201d in pharmaceutical industry: evidence from China\u2019s centralized procurement. Health Econ Rev. 2021;11:23.","journal-title":"Health Econ Rev"},{"issue":"6","key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/blr.2024.31104.hua","article-title":"The redemption of drug patent linkage system: the dilemma and improvement in the qualification system of market exclusivity period for China\u2019s first generic drug","volume":"43","author":"Zhang H","year":"2024","unstructured":"Zhang H, Ji Y. The redemption of drug patent linkage system: the dilemma and improvement in the qualification system of market exclusivity period for China\u2019s first generic drug. Biotechnol Law Rep. 2024;43(6):318\u2013331.","journal-title":"Biotechnol Law Rep"},{"key":"e_1_3_5_10_1","doi-asserted-by":"crossref","first-page":"1557876","DOI":"10.3389\/fphar.2025.1557876","article-title":"Different routes the same destination: a comparative study of antitrust regulation for pharmaceutical industry in the United States and China","volume":"16","author":"Weng J","year":"2025","unstructured":"Weng J, Liu N. Different routes the same destination: a comparative study of antitrust regulation for pharmaceutical industry in the United States and China. Front Pharmacol. 2025;16:1557876.","journal-title":"Front Pharmacol"},{"key":"e_1_3_5_11_1","doi-asserted-by":"crossref","first-page":"1223056","DOI":"10.3389\/fphar.2023.1223056","article-title":"Seven-year exclusivity and beyond for drugs of rare diseases in China","volume":"14","author":"Jiang Y","year":"2023","unstructured":"Jiang Y, Huang H, Zhao G, et al. Seven-year exclusivity and beyond for drugs of rare diseases in China. Front Pharmacol. 2023;14:1223056.","journal-title":"Front Pharmacol"},{"key":"e_1_3_5_12_1","volume-title":"Pharmaceutical policy in China: challenges and opportunities for reform","author":"Kanavos P","year":"2019","unstructured":"Kanavos P, Mills M, Zhang A. Pharmaceutical policy in China: challenges and opportunities for reform. London: LSE Health; 2019."},{"key":"e_1_3_5_13_1","first-page":"14","article-title":"Does the first generic exclusivity system provide an economic incentive for early generic entrance? Evidence from South Korea","author":"Son KB.","year":"2023","unstructured":"Son KB. Does the first generic exclusivity system provide an economic incentive for early generic entrance? Evidence from South Korea. Front Pharmacol. 2023;14.","journal-title":"Front Pharmacol"},{"issue":"5","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.apsb.2013.07.004","article-title":"Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984","volume":"3","author":"Boehm G","year":"2013","unstructured":"Boehm G, Yao L, Han L, et al. Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984. Acta Pharm Sin B. 2013;3(5):297\u2013311.","journal-title":"Acta Pharm Sin B"},{"key":"e_1_3_5_15_1","volume-title":"China\u2019s pharmaceutical patent linkage system: a comparative analysis with the US Hatch-Waxman Act","author":"Brown Mayer","year":"2022","unstructured":"Mayer Brown. China\u2019s pharmaceutical patent linkage system: a comparative analysis with the US Hatch-Waxman Act. Mayer Brown Perspectives; 2022."},{"key":"e_1_3_5_16_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0169-7218(10)01012-9","volume-title":"Handbook of the economics of innovation","author":"Scherer FM.","year":"2010","unstructured":"Scherer FM. Pharmaceutical innovation. In: Hall BH, Rosenberg N, editors. Handbook of the economics of innovation. Vol. 1. Amsterdam: Elsevier; 2010. p. 539\u2013574."},{"issue":"2","key":"e_1_3_5_17_1","first-page":"643","article-title":"Supporting the rationale behind the Hatch-Waxman Act and patent law: how reverse payment settlements under FTC v. Actavis, Inc. can be procompetitive","volume":"12","author":"Podgorny AE.","year":"2015","unstructured":"Podgorny AE. Supporting the rationale behind the Hatch-Waxman Act and patent law: how reverse payment settlements under FTC v. Actavis, Inc. can be procompetitive. Indiana Health Law Rev. 2015;12(2):643\u2013674.","journal-title":"Indiana Health Law Rev"},{"issue":"3","key":"e_1_3_5_18_1","first-page":"947","article-title":"Earning exclusivity: generic drug incentives and the Hatch-Waxman Act","volume":"77","author":"Hemphill CS","year":"2011","unstructured":"Hemphill CS, Lemley MA. Earning exclusivity: generic drug incentives and the Hatch-Waxman Act. Antitrust Law J. 2011;77(3):947\u2013989.","journal-title":"Antitrust Law J"},{"issue":"2","key":"e_1_3_5_19_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1257\/jel.20161327","article-title":"Economics of the pharmaceutical industry","volume":"56","author":"Lakdawalla DN.","year":"2018","unstructured":"Lakdawalla DN. Economics of the pharmaceutical industry. J Econ Lit. 2018;56(2):397\u2013449.","journal-title":"J Econ Lit"},{"issue":"2","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1108\/IJPHM-11-2013-0063","article-title":"Pioneering advantage in generic drug competition","volume":"8","author":"Yu Y","year":"2014","unstructured":"Yu Y, Gupta S. Pioneering advantage in generic drug competition. Int J Pharm Healthc Mark. 2014;8(2):126\u2013150.","journal-title":"Int J Pharm Healthc Mark"},{"issue":"4","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mde.1356","article-title":"Generic competition and market exclusivity periods in pharmaceuticals","volume":"28","author":"Grabowski HG","year":"2007","unstructured":"Grabowski HG, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Manag Decis Econ. 2007;28(4\u20135):491\u2013502.","journal-title":"Manag Decis Econ"},{"key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpubeco.2016.11.010","article-title":"Innovation under regulatory uncertainty: evidence from medical technology","volume":"145","author":"Stern AD.","year":"2017","unstructured":"Stern AD. Innovation under regulatory uncertainty: evidence from medical technology. J Public Econ. 2017;145:181\u2013200.","journal-title":"J Public Econ"},{"issue":"1","key":"e_1_3_5_23_1","first-page":"1","article-title":"Executive pharmaceutical background, R&D investment and corporate innovation performance","volume":"21","author":"Zhang L","year":"2023","unstructured":"Zhang L, Li S, Wu M. Executive pharmaceutical background, R&D investment and corporate innovation performance. J Transl Med. 2023;21(1):1\u201315.","journal-title":"J Transl Med"},{"issue":"16","key":"e_1_3_5_24_1","first-page":"1952","article-title":"Investor attention and corporate innovation performance: evidence from web search volume index of Chinese listed companies","volume":"9","author":"Li N","year":"2021","unstructured":"Li N, Li C, Yuan R, et al. Investor attention and corporate innovation performance: evidence from web search volume index of Chinese listed companies. Mathematics. 2021;9(16):1952.","journal-title":"Mathematics"},{"issue":"1","key":"e_1_3_5_25_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2307\/1912352","article-title":"Sample selection bias as a specification error","volume":"47","author":"Heckman JJ.","year":"1979","unstructured":"Heckman JJ. Sample selection bias as a specification error. Econometrica. 1979;47(1):153\u2013161.","journal-title":"Econometrica"},{"key":"e_1_3_5_26_1","first-page":"167","article-title":"Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry","volume":"12","author":"Tyagi S","year":"2018","unstructured":"Tyagi S, Nauriyal DK, Gulati R. Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry. Rev Manag Sci. 2018;12:167\u2013202.","journal-title":"Rev Manag Sci"},{"key":"e_1_3_5_27_1","article-title":"Can policy advantages be transformed into environmental benefits? City-level evidence from a quasi-natural experiment in China","author":"Guo C","year":"2025","unstructured":"Guo C, Zhou J. Can policy advantages be transformed into environmental benefits? City-level evidence from a quasi-natural experiment in China. Clean Technol Environ Policy. 2025.","journal-title":"Clean Technol Environ Policy"},{"issue":"1","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1162\/003355304772839588","article-title":"How much should we trust differences-in-differences estimates?","volume":"119","author":"Bertrand M","year":"2004","unstructured":"Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Q J Econ. 2004;119(1):249\u2013275.","journal-title":"Q J Econ"},{"issue":"1","key":"e_1_3_5_29_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum PR","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"2","key":"e_1_3_5_30_1","first-page":"e0312345","article-title":"R&D investment and total factor productivity in China\u2019s pharmaceutical industry: the moderating effect of the centralized procurement policy","volume":"20","author":"Li X","year":"2025","unstructured":"Li X, Xu J. R&D investment and total factor productivity in China\u2019s pharmaceutical industry: the moderating effect of the centralized procurement policy. PLoS ONE. 2025;20(2):e0312345.","journal-title":"PLoS ONE"},{"issue":"4","key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jhealeco.2008.01.002","article-title":"Market incentives and pharmaceutical innovation","volume":"27","author":"Yin W.","year":"2008","unstructured":"Yin W. Market incentives and pharmaceutical innovation. J Health Econ. 2008;27(4):1060\u20131077.","journal-title":"J Health Econ"},{"issue":"2","key":"e_1_3_5_32_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1377\/hlthaff.2014.1047","article-title":"The roles of patents and research and development incentives in biopharmaceutical innovation","volume":"34","author":"Grabowski HG","year":"2015","unstructured":"Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff. 2015;34(2):302\u2013310.","journal-title":"Health Aff"},{"issue":"3","key":"e_1_3_5_33_1","first-page":"445","article-title":"A tale of two paths: performance heterogeneity driven by resource employments in the pharmaceutical industry","volume":"58","author":"Liou F.","year":"2020","unstructured":"Liou F. A tale of two paths: performance heterogeneity driven by resource employments in the pharmaceutical industry. Manag Decis. 2020;58(3):445\u2013463.","journal-title":"Manag Decis"},{"key":"e_1_3_5_34_1","article-title":"Early-stage pharmaceutical market structures between originators and first generics after introducing the patent linkage system in South Korea","author":"Son KB.","year":"2026","unstructured":"Son KB. Early-stage pharmaceutical market structures between originators and first generics after introducing the patent linkage system in South Korea. Int J Soc Determ Health Health Serv. 2026.","journal-title":"Int J Soc Determ Health Health Serv"},{"issue":"6","key":"e_1_3_5_35_1","first-page":"1165","article-title":"The impact of product portfolio strategy on financial performance: the roles of product development and market entry decisions","volume":"31","author":"Kang W","year":"2014","unstructured":"Kang W, Montoya M. The impact of product portfolio strategy on financial performance: the roles of product development and market entry decisions. J Prod Innov Manag. 2014;31(6):1165\u20131188.","journal-title":"J Prod Innov Manag"},{"key":"e_1_3_5_36_1","first-page":"112233","article-title":"Does China\u2019s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on difference-in-differences method","volume":"14","author":"Gu Y","year":"2023","unstructured":"Gu Y, Zhuang Q. Does China\u2019s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on difference-in-differences method. Front Pharmacol. 2023;14:112233.","journal-title":"Front Pharmacol"},{"issue":"2","key":"e_1_3_5_37_1","first-page":"834","article-title":"New product development in the pharmaceutical industry: evidence from a generic market","volume":"16","author":"Yousefi N","year":"2017","unstructured":"Yousefi N, Mehralian G, Rasekh HR, et al. New product development in the pharmaceutical industry: evidence from a generic market. Iran J Pharm Res. 2017;16(2):834\u2013846.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_5_38_1","volume-title":"Computational Intelligence in Healthcare Law","author":"Wongmahesak K.","year":"2025","unstructured":"Wongmahesak K. Balancing innovation and access: the role of intellectual property in healthcare. In: Computational Intelligence in Healthcare Law. Taylor & Francis; 2025."},{"issue":"3","key":"e_1_3_5_39_1","first-page":"e007880","article-title":"Improving access to medicines: lessons from 10 years of drug reforms in China, 2009\u20132020","volume":"7","author":"Mao W","year":"2022","unstructured":"Mao W, Jiang H, Mossialos E, et al. Improving access to medicines: lessons from 10 years of drug reforms in China, 2009\u20132020. BMJ Glob Health. 2022;7(3):e007880.","journal-title":"BMJ Glob Health"},{"issue":"1","key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1257\/aer.20141482","article-title":"Patents and the global diffusion of new drugs","volume":"106","author":"Cockburn IM","year":"2016","unstructured":"Cockburn IM, Lanjouw JO. Patents and the global diffusion of new drugs. Am Econ Rev. 2016;106(1):136\u2013164.","journal-title":"Am Econ Rev"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2715978","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2026.2715978","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2715978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:05:41Z","timestamp":1787558741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2715978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":39,"alternative-id":["10.1080\/14737167.2026.2715978"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2715978","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"14737167.2026.2715978"}}